Teva Pharmaceuticals
U.S. Headquarters
1090 Horsham Road
North Wales
Pennsylvania
19454
United States
Tel: 888-838-2872
Website: https://www.tevausa.com/
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
YEAR FOUNDED:
1901
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1660 articles with Teva Pharmaceuticals
-
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
1/18/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2021 financial results, as well as on its financial guidance for 2022, on Wednesday, February 9, 2022 at 7:00 a.m. ET.
-
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.
-
Teva Statement Following New York Jury Ruling in Opioids Trial
12/30/2021
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) strongly disagrees with today’s outcome and will prepare for a swift appeal as well as continue to pursue a mistrial.
-
Teva Pharmaceuticals will appeal a potential $1.5 billion judgment against the company in the state of New York for its alleged role in the opioid epidemic.
-
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
12/22/2021
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of a first-to-market generic version of Narcan®1 (naloxone hydrochloride nasal spray), in the United States.
-
Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.
-
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
-
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
12/1/2021
Teva Pharmaceuticals today announced the launch of an authorized generic of Epiduo® 1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States.
-
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
-
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
11/10/2021
Teva Pharmaceutical Industries Ltd. announced the early tender results in connection with its previously announced tender offers and that it is increasing the combined aggregate purchase price from $3,500,000,000 to $4,000,000,000 for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva.
-
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
-
Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets
11/3/2021
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced ambitious commitments to address two of today’s greatest global crises—access to medicines and climate change—tied to its recently issued $5 billion sustainability-linked bond.
-
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
11/2/2021
Teva Pharmaceutical Industries Ltd. announced that it successfully upsized and priced approximately $5,000,000,000 of its debut sustainability-linked senior notes.
-
Phase 3 Data of mdc-IRM, First Product Based On MedinCell’s Technology, Shows Significant Improvements in Patients With Schizophrenia:
11/1/2021
Developed in collaboration with Teva Pharmaceuticals, mdc-IRM, a risperidone extended-release injectable suspension for the treatment of patients with schizophrenia
-
Researchers found that those who took either the once-a-month or once-every-two-month doses experienced longer periods before relapsing.
-
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
10/30/2021
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced results from the pivotal Phase 3 Risperidone Subcutaneous Extended-release study comparing TV-46000/mdc-IRM once monthly and TV-46000/mdc-IRM once every two months with placebo in patients with schizophrenia who underwent stabilization on oral risperidone.
-
Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.
-
The decision came following negative feedback from both U.S. and European regulators.
-
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
10/21/2021
Teva Pharmaceuticals today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets.
-
MedinCell: mdc-IRM’s Phase 3 Data to Be Presented for the First Time by Teva at Psych Congress 2021 (Oct. 29-Nov. 1, 2021, San Antonio, USA)
10/21/2021
mdc-IRM [Teva’s codename: TV46000], a subcutaneous risperidone injectable suspension for the treatment of patients with schizophrenia, is the most advanced investigational product based on MedinCell’s (Paris:MEDCL) BEPO® technology.